Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Styrene SCHEMBL17746691 | 0.97 | THRB (0.53) | THRBTSHRHPGDLMNAALDH1A1 | |
| Styrene SCHEMBL28806445 | 0.97 | THRB (0.53) | THRBTSHRHPGDLMNAALDH1A1 | |
| Styrene SCHEMBL10906129 | 0.94 | TSHR (0.54) | THRBTSHRHPGDLMNAALDH1A1 | |
| Styrene SCHEMBL28739829 | 0.93 | THRB (0.49) | THRBTSHRHPGDLMNAALDH1A1 | |
| Styrene SCHEMBL10903544 | 0.92 | THRB (0.48) | THRBTSHRHPGDLMNAALDH1A1 | |
| Styrene SCHEMBL67823 | 0.91 | TSHR (0.67) | THRBTSHRHPGDLMNAALDH1A1 | |
| Styrene SCHEMBL3696057 | 0.91 | TSHR (0.67) | THRBTSHRHPGDLMNAALDH1A1 | |
| Styrene SCHEMBL3196230 | 0.91 | TSHR (0.67) | THRBTSHRHPGDLMNAALDH1A1 | |
| Styrene SCHEMBL28887747 | 0.91 | TSHR (0.67) | THRBTSHRHPGDLMNAALDH1A1 | |
| Styrene SCHEMBL28045943 | 0.90 | HCAR2 (0.56) | THRBTSHRLMNAALDH1A1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114524853-B | All-trans retinoic acid-aryl metal complex, preparation method and application | 南京师范大学 | 2023-12-12 | — | — | CN | claimed |
| CN-115160377-B | Semi-sandwich type amino imine [ N, NH ] complex, preparation method and application thereof | 曲阜师范大学 | 2023-12-08 | — | — | CN | claimed |
| CN-116731080-A | Neutral semi-sandwich type [ N, NH ] complex with anticancer activity, and preparation method and application thereof | 曲阜师范大学 | 2023-09-12 | — | — | CN | claimed |
| CN-116715702-A | 16-electron half-sandwich cationic complex with anticancer activity and preparation method and application thereof | 曲阜师范大学 | 2023-09-08 | — | — | CN | claimed |
| CN-113651856-B | Phosphinimine zwitterionic complex and ligand, preparation method and application thereof | 曲阜师范大学 | 2023-08-25 | — | — | CN | claimed |
| CN-116143843-A | Metal complex with FTO inhibition activity and preparation method and application thereof | 南京师范大学 | 2023-05-23 | — | — | CN | claimed |
| CN-115160377-A | Semi-sandwich type amino imine [ N, NH ] complex and preparation method and application thereof | 曲阜师范大学 | 2022-10-11 | — | — | CN | claimed |
| CN-114524853-A | All-trans retinoic acid-aryl metal complex, preparation method and application | 南京师范大学 | 2022-05-24 | — | — | CN | claimed |
| CN-113651856-A | Phosphine zwitterionic complex and ligand, preparation method and application thereof | 曲阜师范大学 | 2021-11-16 | — | — | CN | claimed |
| CN-112745356-A | Bridged aromatic ruthenium dimer compound and preparation method thereof, aromatic ruthenium compound and preparation method and application thereof | 广东药科大学 | 2021-05-04 | — | — | CN | claimed |
| US-9233995-B2 | Quinazoline derivatives and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-01-12 | — | — | US | claimed |
| CN-105152989-A | Preparation method of (1R,2R)-1-substituted-phenyl-2-amino-1,3-propanediol | UNIV FUDAN | 2015-12-16 | — | — | CN | claimed |
| CN-104941637-A | Metal catalyst and preparation method as well as application thereof in cyclohexane preparation by selective hydrogenation of benzene | UNIV SHANGHAI JIAOTONG | 2015-09-30 | — | — | CN | claimed |
| CN-103864665-A | Preparation method of bazedoxifene acetate | SUZHOU TERUI PHARMACEUTICAL CO LTD | 2014-06-18 | — | — | CN | claimed |
| CN-103804427-A | Aryl primary amine ruthenium complex, preparation method and application thereof | UNIV WENZHOU | 2014-05-21 | — | — | CN | claimed |
| CN-103755744-A | Pyridine primary amine ruthenium complex as well as preparation method and application thereof | UNIV WENZHOU | 2014-04-30 | — | — | CN | claimed |
| EP-2634178-A1 | QUINAZOLINE DERIVATIVE AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICATION OF TUMOR CELLS AND PREPARATION METHOD THEREOF | Institute Of Chemistry, Chinese Academy Of Sciences (CN) | 2013-09-04 | — | — | EP | claimed |
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCE (CN) | 2013-08-29 | — | — | US | claimed |
| CN-103044192-A | Method for synthesizing luliconazole intermediate-(S)-2,4-dichloro-1-(1,2-dichloroethyl) benzene | ASTATECH CHENGDU PHARMACEUTICAL CO LTD | 2013-04-17 | — | — | CN | claimed |
| US-20030180647-A1 | Toner processes | XEROX CORPORATION | 2003-09-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | MAP3K21, MAP3K15, MAP3K14 | THRB 3426/4885TSHR 3993/4885HPGD 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.